Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Sagimet Biosciences Inc. Series A Common Stock (SGMT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/27/2025: SGMT (3-star) is a STRONG-BUY. BUY since 18 days. Profits (116.80%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
7 Analysts rated it
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Year Target Price $27.43
Year Target Price $27.43
| 5 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Under performing |
| 0 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit 125.23% | Avg. Invested days 27 | Today’s Advisory Regular Buy |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 06/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 253.38M USD | Price to earnings Ratio - | 1Y Target Price 27.43 |
Price to earnings Ratio - | 1Y Target Price 27.43 | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 1.73 - 10.43 | Updated Date 06/29/2025 |
52 Weeks Range 1.73 - 10.43 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.78 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -24.05% | Return on Equity (TTM) -34.72% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 108686387 | Price to Sales(TTM) 52.5 |
Enterprise Value 108686387 | Price to Sales(TTM) 52.5 | ||
Enterprise Value to Revenue 0.28 | Enterprise Value to EBITDA -1.93 | Shares Outstanding 30674900 | Shares Floating 23234415 |
Shares Outstanding 30674900 | Shares Floating 23234415 | ||
Percent Insiders 13.31 | Percent Institutions 45.88 |
Analyst Ratings
Rating 4.71 | Target Price 27.43 | Buy 2 | Strong Buy 5 |
Buy 2 | Strong Buy 5 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Sagimet Biosciences Inc. Series A Common Stock
Company Overview
History and Background
Sagimet Biosciences is a clinical-stage biopharmaceutical company focused on developing novel therapeutics targeting dysfunctional metabolic pathways in diseases such as nonalcoholic steatohepatitis (NASH) and cancer. Founded in 2006 and went public in April 2023. Has focused on developing fatty acid synthase (FASN) inhibitors.
Core Business Areas
- NASH Drug Development: Focuses on developing Denifanstat, a FASN inhibitor, for the treatment of NASH. This is their lead drug candidate.
- Oncology Drug Development: Exploring the use of FASN inhibitors in cancer treatment.
Leadership and Structure
The leadership team includes executives with experience in drug development and commercialization. The company has a board of directors overseeing strategic direction.
Top Products and Market Share
Key Offerings
- Denifanstat (TVB-2640): A FASN inhibitor in Phase 2b clinical trials for NASH. No current market share as it's not yet approved. Competitors include Madrigal Pharmaceuticals (resmetirom, approved), Viking Therapeutics (VK2809), and Akero Therapeutics (efruxifermin). Revenue is currently $0.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive, with companies focused on developing innovative therapies for unmet medical needs. The NASH market is particularly attractive due to the lack of approved therapies and a growing patient population.
Positioning
Sagimet is positioned as a company developing a novel FASN inhibitor for NASH and oncology. Their competitive advantage lies in their specific mechanism of action and potential efficacy in treating NASH.
Total Addressable Market (TAM)
The NASH market is projected to reach billions of dollars. Sagimet aims to capture a significant share of this market with Denifanstat. Exact TAM estimates vary, but some anticipate it exceeding $40 billion in the coming years. Sagimet, if successful, could capture a multi-billion dollar share.
Upturn SWOT Analysis
Strengths
- Novel FASN inhibitor mechanism
- Promising Phase 2b clinical trial results for Denifanstat in NASH
- Experienced management team
- Strong intellectual property portfolio
Weaknesses
- Reliance on a single lead product candidate
- High cash burn rate associated with drug development
- Clinical trial risks and regulatory hurdles
- Limited commercial infrastructure
Opportunities
- Potential to secure regulatory approval for Denifanstat in NASH
- Expansion of Denifanstat into other indications, such as oncology
- Partnerships with larger pharmaceutical companies
- Growing prevalence of NASH worldwide
Threats
- Competition from other companies developing NASH therapies
- Failure of clinical trials
- Adverse regulatory decisions
- Changes in the healthcare landscape
Competitors and Market Share
Key Competitors
- MDGL
- VKTX
- AKRO
Competitive Landscape
Sagimet faces intense competition in the NASH market. Their advantage lies in the FASN inhibitor mechanism, but they must demonstrate superior efficacy and safety compared to competitors' therapies.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by R&D advancement and clinical trial progression, rather than revenue generation.
Future Projections: Future growth depends on the successful completion of clinical trials, regulatory approval of Denifanstat, and commercialization. Analyst estimates vary widely depending on these factors.
Recent Initiatives: Recent initiatives include completing Phase 2b trials for Denifanstat, preparing for Phase 3 trials, and exploring potential partnerships.
Summary
Sagimet is a clinical-stage biopharmaceutical company with a promising drug candidate, Denifanstat, targeting NASH. Its success hinges on positive clinical trial results and regulatory approval. The company faces significant competition and financial risks typical of early-stage biotech companies. A solid market position can be obtained through partnerships and market penetration after regulatory approval. The company should work to reduce its cash burn rate.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (SEC)
- Company Website
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered as financial advice. Investment decisions should be based on thorough research and consultation with a financial professional. Market share data is an approximation based on currently approved drugs or drugs closest to approval. Projections are based on available information and subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Sagimet Biosciences Inc. Series A Common Stock
Exchange NASDAQ | Headquaters San Mateo, CA, United States | ||
IPO Launch date 2023-07-14 | CEO, President & Director Mr. David A. Happel | ||
Sector Healthcare | Industry Biotechnology | Full time employees 14 | Website https://www.sagimet.com |
Full time employees 14 | Website https://www.sagimet.com | ||
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs, such as various solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.